5,6-Dimethoxy-2,3-Dihydro-1H-Inden-1-One

2107-69-9

Chenglian Pharmaceutical is an innovative high-tech£ pharmaceutical enterprise that is market-oriented and realizes industrial dev©elopment through R&D innovation and technology transformation.

key word:

innovative Pharmaceutical

Category:

Product Description

Integrity, innovation, cooperation, sharing, win-win

The company integrates multiple resources and strives to build a laφrge health industry finance platform company integrating pharmaceutical, intell™igent medical, bio pharmaceutical R&D, industrial production and sales.

The chemical reactions involved in the existing products include Foucault reaction, nitration reactαion, sulfonation reaction, hydrogenation reaction, fluorination reactio$n, chlorination reaction, bromination reaction, diazotization r​eaction, format reaction, etc.

Related products

Sitagliptin Phosphate Monohydrate

Sitagliptin phosphate is a dipeptidyl peptidase-4 (DPP4) inhibitor develope♦d by Merck. In October 2006, Sitagliptin phosphate Januvia was approved by FDA →as the first DPP4 inhibitor for the treatment of typ©e ⅱ diabetes mellitus. The characteristics of this drug are that it can stimulate insulin se$cretion while reducing hunger without causing weight gain. Hypoglycemia and edema will not© occur, and it is suitable for diabetic patients with poor blood glucose control and frequ∏ent hypoglycemia.

Sumatriptan Succinate

Medication for migraine

Vildagliptin

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise t<hat is market-oriented and realizes industrial development through R☆&D innovation and technology transformation.

Ketoprofen

The non-steroidal anti-inflammatory drug ketoprofen is one≤ of the most important products for the treatment of artγhritis. It is well tolerated and has a low incidence of ←side effects

Pranlukast

Pranlukast, developed by Ono, is one of the three major leukotriene receptor antagonists. I‍n clinical application, it has good therapeutic effect ≥on atopic asthma and other types of bronchial asthma, and the market prospect is hu‍ge. In the major category of asthma drugs, leukotriene rec÷eptor antagonists have the fastest growing market share.

Avanafil

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that is ma>rket-oriented and realizes industrial development t≤hrough R&D innovation and technology transformation.

Donepezil HCL

Treatment of mild to moderate Alzheimer's syndrome. It is the second drug approved by F→DA for Alzheimer's disease in the United States. Its treatment reaches the targe$t dose and has low toxic and side effects. It has been widely recognized by our medi cal community, and good tolerance is its biggest advantage. In October 1999, Donepezil was lεaunched in China under the trade name "Aricept", which is the main chemical drug againsλt Alzheimer's disease. At present, CFDA has approved a number of domestic enterprises to p'roduce donepezil preparations, the main dosage forms are tablets, capsules$, dispersive tablets, oral disintegrating tablets.

Almotriptan

Migraine medication for adolescents

Apixaban

English name Apixaban Trade name ELIQUIS, tablet: Apixaban (El∞iquis, Bristol-Myers Squibb/Pfizer), a direct oral factor Xa inhibitor, wαas approved for use in the 27 EU member states. The world's first drug≥ approved to prevent venous thromboembolism (VTE) in adult patients undergoing elective hip™ or knee replacement. From June 2019 to June 2020, the ann ual sales of apixaban products overseas reached about $15♠.4 billion, with a year-on-year growth of nearly 32%, and the API consumption reache↔d about 23,960 kg, with a year-on-year growth of about 28%. ♠Compared with its main competitor, Rivaroxaban, the drug's annual overseas sales are about $4.5 bil≤lion higher.

Lenvatinib

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise th←at is market-oriented and realizes industrial development through R&D €innovation and technology transformation.

Clofarabine

It is a nucleotide analogue developed by Bioenvision and manufactured by ©Genzyme. On December 29, 2004, it was approved by FDA for the treatment of refractory or relapsed a∞cute lymphoblastic leukemia (ALL) in children.

Upadacitinib(Scientific research)

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that is mar≠ket-oriented and realizes industrial development through R&D inδnovation and technology transformation.

Product Consulting

Our staff will contact you within 24 hours (working days). 'If you need other services, E-mail: 2880705932@qq.com

Copyright © 2022 Anhui Union Pharmaceuticals Technol≥ogy Co., Ltd.